5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT03366116

Status	RECRUITING
Phase	Phase 1
Sponsor	National Cancer Institute (NCI)
Enrollment	65 participants

Key Eligibility Criteria

Inclusion (20)

- Patients must have histologically documented solid tumors whose disease has progressed on standard therapy or for which there is no available standard therapy.
- Age \>=18 years of age.
- ECOG performance status \<= 2.
- Patients must have normal organ and marrow function as defined below:
- absolute neutrophil count \>= 1,500/mcL

... and 15 more (see full listing online)

Exclusion (14)

- Patients who are receiving any other investigational agents.
- Pregnant women and women who are breastfeeding are excluded from this study.
- Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known HIV infection requiring protease inhibitor therapy, known Hepatitis B, known Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions:
- Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:

... and 9 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States